Patterns of treatment and outcomes of patients with metastatic HER2-low breast cancer treated with CDK4/6 inhibitors and hormone therapy

Background: The 2018 American Society of Clinical Oncology/College of American Pathologists guidelines classified immunohistochemistry (IHC) 1+ or 2+, FISH-negative breast cancer as HER2-low. To date, only a few studies have investigated the role of HER2-low status in patients with hormone receptor...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Federico Sottotetti, Barbara Tagliaferri, Gianpiero Rizzo, Raffaella Palumbo, Giulia Chessa, Chiara Raso, Lorenzo Perrone, Alberto Malovini, Valentina Tibollo, Laura Deborah Locati, Paolo Pedrazzoli, Angioletta Lasagna
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	BioExcel Publishing Ltd 2025-05-01
Serie:	Drugs in Context
Soggetti:	abemaciclib antibody–drug conjugates her2-low metastatic breast cancer palbociclib ribociclib therapeutic strategies
Accesso online:	https://www.drugsincontext.com/patterns-of-treatment-and-outcomes-of-patients-with-metastatic-her2-low-breast-cancer-treated-with-cdk4-6-inhibitors-and-hormone-therapy/
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!